Attached files

file filename
EX-31.2 - EX-31.2 - ImmunoCellular Therapeutics, Ltd.imuc-ex312_201409308.htm
EX-32.1 - EX-32.1 - ImmunoCellular Therapeutics, Ltd.imuc-ex321_201409306.htm
EX-31.1 - EX-31.1 - ImmunoCellular Therapeutics, Ltd.imuc-ex311_201409309.htm
EXCEL - IDEA: XBRL DOCUMENT - ImmunoCellular Therapeutics, Ltd.Financial_Report.xls
10-Q - 10-Q - ImmunoCellular Therapeutics, Ltd.imuc-10q_20140930.htm

Exhibit 32.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:

1.

The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2014 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 10, 2014

By:

/s/ David Fractor 

 

 

Name:

David Fractor

 

 

Title:

Principal Financial and Accounting Officer